An interventional study of Virtual Mindfulness Based Stress Reduction Group and Virtual sarcoidosis support group in Sarcoidosis, Fatigue and Depression, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Sarcoidosis with a site in United States — 23 open to participants now, 25 under way, 3 of them phase 3. Sarcoidosis · United States.
Among the 115 studies in Sarcoidosis with a site in United States, this one is the 9th largest by planned enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 with no phase, reaches primary completion later than 12 of the 24 other live ones, and was the 112th registered.
271 studies on the registry are indexed under Sarcoidosis; 51 are open to participants now.
Browse Sarcoidosis studies →23 of the 115 studies in Sarcoidosis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18–85
Duke University · Sites in United States
Ages 18+
Priovant Therapeutics, Inc. · Sites in United States, Australia, United Kingdom
Ages 18+
University of Pennsylvania · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Sarcoidosis studies recruiting now, 30 (73%) set no upper age limit and 1 (2%) stops at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 37 · Phase 3 10 · Phase 4 12
First in 1978; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 50 across 145 interventional studies indexed under Sarcoidosis.
Median enrollment 16 across the 69 interventional studies, 200 across the 46 observational. Of the 73 that completed or were terminated, 30 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 115 have an industry lead sponsor. The 10 most frequent:
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
The Cleveland Clinic has 2 studies filed under Sarcoidosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Sarcoidosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03593759Phase 3Ottawa Heart Institute Research CorporationCardiac Sarcoidosis Randomized Trial | 2026-12 |
| NCT03621553University of Texas Southwestern Medical CenterVitamin D Homeostasis in Sarcoidosis | 2026-12 |
| NCT07159074Duke UniversityRepurposing Tilmanocept for Cardiac Sarcoidosis | 2026-12-01 |
| NCT05171478Johns Hopkins UniversityFull-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens | 2026-12-08 |
| NCT06510894University of PennsylvaniaDiagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 115 studies in Sarcoidosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study is testing whether Mindfulness-Based Stress Reduction (MBSR) can help reduce fatigue in people with sarcoidosis. The study will also look at whether MBSR can improve symptoms of anxiety and depression.
Participants will be placed into one of two groups:
The goal is to see which approach is more helpful for improving fatigue and mental well-being in people with sarcoidosis.
Fatigue is a common and debilitating symptom of sarcoidosis. There are currently no approved treatments for sarcoidosis associated fatigue. We are testing an MBSR intervention based on previous work showing improvement of sarcoidosis associated fatigue with mindfulness interventions.
Participants will be adults diagnosed with sarcoidosis per self report and experiencing significant fatigue (Fatigue Assessment Scale [FAS] score ≥22). Participants will be recruited through Cleveland Clinic and partnering sarcoidosis clinics. Recruitment includes both in-person and virtual strategies using electronic health record (EHR) screening, MyChart messages, clinician referrals, and self-referral through a recruitment letter. Interested patients will complete eligibility screening, including a virtual or in-person consent process and FAS assessment.
Following enrollment, participants will be randomized 1:1 to either the MBSR intervention or control group (support group). The MBSR intervention consists of 8 weekly, virtual group sessions led by trained facilitators and includes guided mindfulness practices, group discussions, and home practice assignments. The control group will participate in an existing monthly virtual sarcoidosis support group, which includes a brief educational presentation and group discussion.
Study outcomes will be collected using online surveys at three timepoints: baseline (prior to intervention), 8 weeks (immediately post-MBSR), and 5 months (3-month follow-up). Outcomes include fatigue (primary), quality of life, depression, and anxiety. Qualitative interviews will be conducted after the intervention to explore participant experiences with the intervention.
The investigators will conduct an interim analysis to determine feasibility of study for study participants. If there is greater than 30% drop out and drop out assessed by primary investigator, blinded to study results, is determined to be due to intervention components, the study will be paused, the intervention tailored prior to continued recruitment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group will meet with a certified Mindfulness Based Stress Reduction counselor one time a week to learn and practice mindfulness techniques as a means of addressing fatigue and mental health in sarcoidosis. This group will fill out diaries of their use of Mindfulness Based Stress Reduction techniques for the duration of the 8 week intervention and complete fatigue, depression, and anxiety surveys at time 0, 8 weeks, and 5 months.
Behavioral: Virtual Mindfulness Based Stress Reduction Group
This group will be invited to join an existing virtual sarcoidosis support group. They will participate in the group for the 5 months of the trial. They will complete fatigue, depression, and anxiety surveys at time 0, 8 weeks, and 5 months.
Behavioral: Virtual sarcoidosis support group
Mindfulness Based Stress Reduction is an evidence-based, manualized 8-week group program designed to improve coping with chronic physical and psychological symptoms. MBSR emphasizes mindfulness meditation, body awareness, and gentle movement to cultivate nonjudgmental awareness of present-moment experiences and reduce stress reactivity. The intervention will be delivered in a virtual group setting.
Participants attend a once-monthly, virtual support group via secure video conferencing. Each session includes a brief didactic presentation on topics relevant to living with chronic illness (e.g., symptom management, coping strategies, navigating healthcare) followed by a facilitated group discussion. The discussion emphasizes peer support, shared experiences, and emotional processing in a safe, respectful environment. Groups are led by an experienced facilitator with experience in chronic illness care. No home practice is required.
PROMIS Fatigue 8a
validated 8 items fatigue questionnaire reported as an aggregate score
Time frame: From enrollment to the end of the study period at 5 months
Kings Sarcoidosis Questionnaire - General Health
The KSQ General Health is a 10-item self-report survey reported as a single aggregate score which assesses quality of life in sarcoidosis.
Time frame: From enrollment to end of study period at 5 months
Patient Health Questionnaire - 8
It is a self-reported measure of depressive symptom severity and consists of items consistent with criteria for DSM-based diagnosis. PHQ-8 scores range from 0 to 24. Each of the 8 items can be scored from 0 ("not at all") to 3 ("nearly every day"). Cut-points of 5, 10, 15, and 20 represent the thresholds for mild, moderate, moderately severe, and severe depression, respectively. The construct validity of the PHQ-8 has been demonstrated in a wide range of patient populations
Time frame: From enrollment to end of study period at 5 months
Generalized Anxiety Disorder-7
7-item questionnaire that measures frequency of anxiety symptoms over the past 7 days. Response options are scored on a 4-point Likert scale ranging from "not at all" to "nearly every day." The summed score will be reported.
Time frame: From enrollment to end of study period at 5 months
Five Facet of Mindfulness Scale (Short Form; FFMQ-15)
The FFMQ is a measure of treatment fidelity. The FFMQ measures pre-post trait mindfulness and is assessed using 15 items that index the degree to which participants experience daily mindfulness, a central objective of MBSR treatment. Each item is rated on a 5-point scale from '1' = never or very rarely true to '5' = very often or always true. Reported as a single aggregate score
Time frame: From enrollment to end of study period at 5 months
Client Satisfaction Questionnaire (CSQ-8)
The CSQ-8 is a validated questionnaire of patients satisfaction with mental health interventions. It involves summing response to 8 questions on a 4 point scale with scores ranging from 8 to 32.
Time frame: From enrollment to end of study period at 5 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.
Of 32 interventional studies with no phase under Sarcoidosis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 59. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.